Abstracts tagged "bone biology and rheumatoid arthritis (RA)"

Abstract Number: 2212 • 2015 ACR/ARHP Annual Meeting
Identification of a Novel Chemokine-Dependent Molecular Mechanism Underlying Rheumatoid Arthritis-Associated Autoantibody-Mediated Bone Destruction
Akilan Krishnamurthy¹, Vijay Joshua², Aase Haj Hensvold³, Tao Jin⁴, Meng Sun³, Marianne Engström³, Khaled Amara¹, Malin MAgnusson⁴, Camilla Svensson⁵, Vivianne Malmström³, L. Klareskog¹, Heidi Wähämaa³ and Anca I Catrina³, ¹Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Unit of Rheumatology, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ⁴Department of Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, Gothenberg, Sweden, ⁵Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Rheumatoid arthritis (RA)-specific anti-citrullinated protein/peptide antibodies (ACPAs) appear before disease onset and are associated with bone destruction. We aimed to dissect the role of…
Abstract Number: 2622 • 2015 ACR/ARHP Annual Meeting
Serum RANKL Levels, Associate with Anti Citrullinated Proteins Antibodies (ACPA) in Early-Untreated Rheumatoid Arthritis and Is Modulated Following Methotrexate
Aase Haj Hensvold¹, Vijay Joshua¹, K. Lundberg², Nadine A. Defranoux³, Saedis Saevarsdottir⁴ and Anca I Catrina², ¹Rheumatology Unit, Department of Medicine, Solna, Karolinska Institute, Stockholm, Sweden, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ³Crescendo Bioscience Inc., South San Francisco, CA, ⁴Department of Medicine, Rheumatology Unit, The Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Receptor Activator of Nuclear factor Kappa-b Ligand (RANKL) is a key regulator of bone metabolism. Anti-citrullinated (cit) protein antibodies (ACPA) have been suggested to…
Abstract Number: 2797 • 2014 ACR/ARHP Annual Meeting
Anti-Citrullinated Proteins Antibodies Promotes Osteoclastogenesis and Bone Destruction in Rheumatoid Arthritis
Akilan Krishnamurthy¹, Vijay Joshua¹, Heidi Wähämaa¹, Catia Cerqueira¹, Lars Klareskog², Vivianne Malmström³, Jimmy Ytterberg¹ and Anca I Catrina¹, ¹Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ²Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ³Medicine, Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose Presence of anti-citrullinated protein antibodies (ACPA) is a major risk factor for bone erosion in rheumatoid arthritis (RA) and antibodies against modified citrullinated vimentin…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].